Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Vedolizumab
Treatment for Inflammatory bowel disease
Typical Dosage: 300 mg IV every 8 weeks
Effectiveness
80%
Safety Score
60%
Clinical Trials
162
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg IV every 8 weeks
Time to Effect
6-10 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
60(Treat 60 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$35,000
Monitoring:$3,000
Side Effect Mgmt:$1,000
Total Annual:$39,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$70,909
Cost per Remission
$130,000
Comparison vs Infliximab
Cost Difference
+$9,500/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Vedolizumab Outcomes
for Inflammatory bowel disease
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+55%
Remission Rate
+30%
Common Side Effects
Nasopharyngitis
+12%
Headache
+12%
Arthralgia
+10%
Infections (URI, UTI)
+22%
Serious infections
+1.5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Vedolizumab in Inflammatory bowel disease
Subcutaneous Interval Lengthening of Vedolizumab for Economic Research
NCT06584162RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Amsterdam, Netherlands
Started: Feb 9, 2023
VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)
NCT05158517ACTIVE NOT RECRUITING
349 participants
OBSERVATIONAL
Grenoble, France
Started: Mar 20, 2022
Effectiveness and Tolerance of IV vs SC Biological Drugs in Gastrointestinal Diseases
NCT06604728RECRUITING
400 participants
OBSERVATIONAL
Roma, Italy
Started: Sep 4, 2023
Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods
NCT06849739NOT YET RECRUITING
60 participants
OBSERVATIONAL
Guangzhou, China
Started: Mar 2, 2025
Completed Clinical Trials
10 completed trials for Vedolizumab in Inflammatory bowel disease
Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.
NCT02712866COMPLETED
24 participants
OBSERVATIONAL
Barcelona, Spain
Started: Jan 1, 2017
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
NCT02862132COMPLETEDNA
142 participants
INTERVENTIONAL
Hartford, United States +14 more
Started: Jan 1, 2017
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03629379COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Leuven, Belgium
Started: Jan 22, 2019
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
NCT07273760COMPLETED
150 participants
OBSERVATIONAL
Shiraz, Iran +11 more
Started: Jul 16, 2023
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
NCT01981616COMPLETEDPHASE1
127 participants
INTERVENTIONAL
Manchester, United Kingdom
Started: Sep 1, 2011
Defining Predictors of RT Response to Vedolizumab in IBD
NCT03142321COMPLETEDPHASE4
48 participants
INTERVENTIONAL
St Louis, United States
Started: Jun 8, 2018
Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
NCT03056924COMPLETED
173 participants
OBSERVATIONAL
Boston, United States
Started: Jul 5, 2017
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
NCT02038920COMPLETEDPHASE3
157 participants
INTERVENTIONAL
Nagoya, Japan +55 more
Started: Jan 28, 2014
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
NCT02425111COMPLETEDPHASE3
101 participants
INTERVENTIONAL
La Jolla, United States +78 more
Started: Mar 30, 2015
Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells
NCT03043677COMPLETED
45 participants
OBSERVATIONAL
Started: Apr 1, 2016
Showing 20 of 170 total trials